Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Cytologically or histologically confirmed diagnosis of 1 of the following:~  * Acute myeloid leukemia, meeting the following criteria:~    * Documented Wilms tumor-1 (WT-1)-positive disease demonstrated by WT-1 protein on a pretreatment bone marrow biopsy OR detectable disease with real-time quantitative reverse transcriptase-polymerase chain reaction (RQ-PCR)~   * Completed induction chemotherapy, achieved clinical remission, and completed postremission therapy OR achieved clinical remission and have no plans for further postremission chemotherapy (≥ 65 years of age)~ * Myelodysplastic syndromes, meeting the following criteria:~    * Documented WT-1-positive disease demonstrated by WT-1 protein on a pretreatment bone marrow biopsy OR detectable disease by RQ-PCR~   * International Prognostic Scoring System (IPSS) score of ≥ Int-2~   * Not a candidate for cytotoxic chemotherapy~ * Non-small cell lung cancer, meeting the following criteria:~    * Positive tumor staining for WT-1 in \> 10% of cells~   * Stage III or IV disease~   * Completed chemotherapy, surgery, and/or radiotherapy~ * Mesothelioma, meeting the following criteria:~    * Positive tumor staining for WT-1 in \> 10% of cells~   * Unresectable or relapsed disease~   * Chemo-naive or received 1 prior chemotherapy regimen~   * Malignant pleural mesothelioma or peritoneal mesothelioma~* No leptomeningeal disease~* No CNS involvement~PATIENT CHARACTERISTICS:~* Karnofsky performance status 70-100%~* Absolute neutrophil count ≥ 1,000/mm³~* Platelet count \> 50,000/mm³ (except for myelodysplastic syndromes where parameter is \> 20,000/mm³ and not transfusion dependent)~* Bilirubin ≤ 2.0 mg/dL~* AST and ALT ≤ 2.5 times upper limit of normal~* Creatinine ≤ 2.0 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No active infection requiring systemic antibiotics, antiviral, or antifungal treatments~* No serious unstable medical illness~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 4 weeks since prior chemotherapy or radiotherapy~* No concurrent systemic corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- vaccine (Type: EXPERIMENTAL): Six vaccinations of the WT-1 peptide (1.0 ml of emulsion) will be administered on weeks 0, 4, 6, 8, 10 \& 12. Vaccinations will be administered subcutaneously with sites rotated among extremities. Injection sites will be pre-stimulated with Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 \& -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) if they have been appropriately instructed on SQ injection administration. Patients will keep a logbook noting the time \& placement of the injection. Note: during each vaccination, the Sargramostim (GM-CSF) \& the vaccine emulsion will be administered to the same anatomical site. This site will be marked by the patient or treating healthcare professional by a permanent marker pen. For patients who have a clinical, molecular, or immunologic response \& have not had disease progression, they may receive up to 6 more vaccinations administered approximately every month.

Based on this trial design, predict the completion outcome and termination type (if applicable).